Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.

Adjuvant chemotherapy may improve survival in resected ampullary adenocarcinoma

18 Aug 2020

Gemcitabine-based adjuvant chemotherapy appears to confer survival benefits to patients with resected ampullary adenocarcinoma, suggests a study. However, this beneficial effect may be exclusive to those with the pancreatobiliary or mixed subtype.

A propensity score-matched analysis was conducted to compare survival between patients with and without adjuvant chemotherapy in this international multicentre cohort study. A total of 1,163 patients who underwent pancreatoduodenectomy for ampullary adenocarcinoma between 2006 and 2017, in 13 centres in six countries, were included.

The authors used propensity scores to match patients who received adjuvant chemotherapy with those who did not in the entire cohort and in two subgroups (ie, pancreatobiliary/mixed and intestinal subtypes). The Kaplan-Meier method and Cox regression analyses were used to assess survival.

Of the patients, 187 were excluded. The median survival in the remaining participants was 67 months (95 percent confidence interval, 56–78). Adjuvant chemotherapy was administered to 520 patients (53.3 percent). In a propensity score-matched cohort (194 patients in each group), survival was better among those who received adjuvant chemotherapy compared to those who did not (median not survival reached vs 60 months; p=0.051).

Patients with the pancreatobiliary/mixed subtype achieved a survival benefit (median survival not reached in patients received adjuvant chemotherapy vs 32 months in the group without chemotherapy; p=0.020). On the other hand, survival benefit from adjuvant chemotherapy was not observed in patients with the intestinal subtype.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Oct 2020

The risk of falls and subsequent injuries (eg, fractures) may be elevated in individuals with diabetes compared with the general population, according to a nationwide cohort study from Denmark.

Audrey Abella, 10 Sep 2020
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
02 Jul 2019
A systematic review has recently described the rudimentary pharmacokinetics of mitragynine, but studies lack information on the role of metabolism and redistribution into tissues or excretion rate.